The Latest Medical News

A Summary of The Latest Medical News: FDA-Approved Diabetes Drug Shows Promise in Reducing Heart Attack and Stroke Risk A groundbreaking study has revealed that a medication already approved by the FDA for treating type 2 diabetes and chronic kidney disease may have additional cardiovascular benefits. The drug, known as sotagliflozin, has been found to significantly lower the risk of heart attack and stroke in patients with these conditions. The research, published in The Lancet Diabetes & Endocrinology, analyzed data from the SCORED trial, which involved nearly 10,600 participants. The study found that those taking sotagliflozin reduced their risk of heart attack, stroke, and death from cardiovascular causes by an impressive 23% compared to those taking a placebo. Dr. Deepak L. Bhatt, lead author of the study and director of Mount Sinai Fuster Heart Hospital, noted that the benefits of the drug were observed within just three months of starting treatment. This rapid effect is particularly remarkable in a stable, outpatient population. Sotagliflozin works by inhibiting both SGLT2 and SGLT1 receptors, which are found in various organs including the kidneys, gut, heart, and brain. This unique mechanism of action may explain why the drug is effective in reducing both heart attack and stroke risks, setting it apart from other medications in its class. The findings of this study are particularly significant for individuals with type 2 diabetes and chronic kidney disease, who are at a higher risk of cardiovascular complications. The multi-pronged approach of sotagliflozin could lead to a substantial reduction in cardiovascular risk for eligible patients. As research continues, scientists are exploring the potential applications of sotagliflozin in other high-risk populations. This promising development offers hope for millions of people living with diabetes and kidney disease, potentially providing them with a powerful tool to protect their heart health. Help with your insurance? https://tally.so/r/n012P9